Skip to main content
CMAJ : Canadian Medical Association Journal logoLink to CMAJ : Canadian Medical Association Journal
. 2024 Oct 15;196(34):E1169. doi: 10.1503/cmaj.240337

Perimenopause

Iliana C Lega 1,, Michelle Jacobson 1
PMCID: PMC11482657  PMID: 39406411

Perimenopause is a clinical diagnosis

According to the Stages of Reproductive Aging Workshop, perimenopause commences with persistent differences in menstrual cycle length by more than 7 days.1 Menopause begins after 12 months of amenorrhea. No laboratory or imaging tests are needed to diagnose perimenopause after age 40 years, given the variability of follicle-stimulating hormone levels during this time and lack of meaningful cut-off values.

Symptoms of hypoestrogenism can start during perimenopause

Fluctuating estrogen levels may cause heavy and irregular bleeding, vasomotor symptoms (i.e., hot flashes and night sweats), mood and memory changes, sleep disturbances, decreased libido, and genitourinary symptoms. These symptoms may precede the last menstrual period by up to 10 years.2

Hormone treatments in perimenopause should be guided by symptoms and need for contraception

Pregnancy can still occur during perimenopause, so contraceptive needs must be addressed. Menopausal hormonal therapy is recommended as the first-line treatment for vasomotor symptoms in perimenopause,3 but those with irregular bleeding or who require contraception may benefit from combined oral contraceptives. Mood disturbances may improve with menopausal hormonal therapy alone, or with serotonin–norepinephrine reuptake inhibitors or selective serotonin reuptake inhibitors. Strong evidence is lacking to support progestogens alone for treating perimenopausal symptoms.

People older than 40 years with new onset of frequent or heavy vaginal bleeding should have transvaginal ultrasonography with endometrial sampling, especially if there are risk factors for endometrial cancer4

Anovulation can cause irregular bleeding in perimenopause and is a risk factor for endometrial hyperplasia and cancer. Other risk factors for endometrial cancer include obesity, exogenous estrogen exposure, hypertension, diabetes, and some genetic predispositions like Lynch syndrome.

Metabolic parameters worsen faster, and more, during perimenopause than after menopause5

Optimizing lifestyle factors during perimenopause (i.e., healthy weight and physical activity) and screening for cardiovascular risk factors are important strategies for reducing the risk of cardiovascular disease in the period after menopause.

Footnotes

Competing interests: Michelle Jacobson sits on advisory boards for Astellas, BioSyent, Duchesnay, Eisai, Knight, Lupin, Pfizer, Canadian Menopause Society, and Menopause Foundation of Canada. She has received honoraria, consulting fees, or both, from Astellas, AbbVie, Bayer, BioSyent, Duchesnay, Knight, Lupin, Organon, Pfizer, and Searchlight, grants or contracts from Health Canada and the Canadian Institutes of Health Research, and support to attend meetings from The Society of Obstetricians and Gynaecologists of Canada. No other competing interests were declared.

This article has been peer reviewed.

References

  • 1.Harlow SD, Gass M, Hall JE, et al.; STRAW + 10 Collaborative Group. Executive summary of the Stages of Reproductive Aging Workshop + 10: addressing the unfinished agenda of staging reproductive aging. J Clin Endocrinol Metab 2012;97:1159–68. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 2.Avis NE, Crawford SL, Greendale G, et al.; Study of Women’s Health Across the Nation. Duration of menopausal vasomotor symptoms over the menopause transition. JAMA Intern Med 2015;175:531–9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 3.“The 2022 Hormone Therapy Position Statement of The North American Menopause Society” Advisory Panel. The 2022 hormone therapy position statement of The North American Menopause Society. Menopause 2022;29:767–94. [DOI] [PubMed] [Google Scholar]
  • 4.Singh S, Best C, Dunn S, et al. No. 292: Abnormal uterine bleeding in pre-menopausal women. J Obstet Gynaecol Can 2018;40:e391–415. [DOI] [PubMed] [Google Scholar]
  • 5.Gurka MJ, Vishnu A, Santen RJ, et al. Progression of metabolic syndrome severity during the menopausal transition. J Am Heart Assoc 2016;5:e003609. doi: 10.1161/JAHA.116.003609. [DOI] [PMC free article] [PubMed] [Google Scholar]

Articles from CMAJ : Canadian Medical Association Journal are provided here courtesy of Canadian Medical Association

RESOURCES